Antibody Drug Conjugate-Global Market Status and Trend Report 2013-2023
Report Summary
Antibody Drug Conjugate-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Antibody Drug Conjugate worldwide, with company and product introduction, position in the Antibody Drug Conjugate market
Market status and development trend of Antibody Drug Conjugate by types and applications
Cost and profit status of Antibody Drug Conjugate, and marketing status
Market growth drivers and challenges
The report segments the global Antibody Drug Conjugate market as:
Global Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Antibody Drug Conjugate Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Adcetris
Kadcyl
Other
Global Antibody Drug Conjugate Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Pharmaceutical Company
Research Institutions
Global Antibody Drug Conjugate Market: Manufacturers Segment Analysis (Company and Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and Gross Margin):
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Antibody Drug Conjugate-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Antibody Drug Conjugate worldwide, with company and product introduction, position in the Antibody Drug Conjugate market
Market status and development trend of Antibody Drug Conjugate by types and applications
Cost and profit status of Antibody Drug Conjugate, and marketing status
Market growth drivers and challenges
The report segments the global Antibody Drug Conjugate market as:
Global Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Antibody Drug Conjugate Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Adcetris
Kadcyl
Other
Global Antibody Drug Conjugate Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Pharmaceutical Company
Research Institutions
Global Antibody Drug Conjugate Market: Manufacturers Segment Analysis (Company and Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and Gross Margin):
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTIBODY DRUG CONJUGATE
1.1 Definition of Antibody Drug Conjugate in This Report
1.2 Commercial Types of Antibody Drug Conjugate
1.2.1 Adcetris
1.2.2 Kadcyl
1.2.3 Other
1.3 Downstream Application of Antibody Drug Conjugate
1.3.1 Hospital
1.3.2 Pharmaceutical Company
1.3.3 Research Institutions
1.4 Development History of Antibody Drug Conjugate
1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
1.5.1 Global Antibody Drug Conjugate Market Status and Trend 2013-2023
1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Antibody Drug Conjugate 2013-2017
2.2 Production Market of Antibody Drug Conjugate by Regions
2.2.1 Production Volume of Antibody Drug Conjugate by Regions
2.2.2 Production Value of Antibody Drug Conjugate by Regions
2.3 Demand Market of Antibody Drug Conjugate by Regions
2.4 Production and Demand Status of Antibody Drug Conjugate by Regions
2.4.1 Production and Demand Status of Antibody Drug Conjugate by Regions 2013-2017
2.4.2 Import and Export Status of Antibody Drug Conjugate by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Antibody Drug Conjugate by Types
3.2 Production Value of Antibody Drug Conjugate by Types
3.3 Market Forecast of Antibody Drug Conjugate by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry
4.2 Market Forecast of Antibody Drug Conjugate by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE
5.1 Global Economy Situation and Trend Overview
5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Antibody Drug Conjugate by Major Manufacturers
6.2 Production Value of Antibody Drug Conjugate by Major Manufacturers
6.3 Basic Information of Antibody Drug Conjugate by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Manufacturer
6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Seattle Genetics/Takeda
7.1.1 Company profile
7.1.2 Representative Antibody Drug Conjugate Product
7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle Genetics/Takeda
7.2 Roche
7.2.1 Company profile
7.2.2 Representative Antibody Drug Conjugate Product
7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche
7.3 ImmunoGen
7.3.1 Company profile
7.3.2 Representative Antibody Drug Conjugate Product
7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen
7.4 Immunomedics
7.4.1 Company profile
7.4.2 Representative Antibody Drug Conjugate Product
7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics
7.5 Pfizer
7.5.1 Company profile
7.5.2 Representative Antibody Drug Conjugate Product
7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer
7.6 Celldex Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody Drug Conjugate Product
7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.7 Millennium Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Antibody Drug Conjugate Product
7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals
7.8 Bayer HealthCare
7.8.1 Company profile
7.8.2 Representative Antibody Drug Conjugate Product
7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.9 Mersana Therapeutics
7.9.1 Company profile
7.9.2 Representative Antibody Drug Conjugate Product
7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana Therapeutics
7.10 Heidelberg Pharma
7.10.1 Company profile
7.10.2 Representative Antibody Drug Conjugate Product
7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Heidelberg Pharma
7.11 Oxford BioTherapeutics
7.11.1 Company profile
7.11.2 Representative Antibody Drug Conjugate Product
7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Antibody Drug Conjugate Product
7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE
8.1 Industry Chain of Antibody Drug Conjugate
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE
9.1 Cost Structure Analysis of Antibody Drug Conjugate
9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate
9.3 Labor Cost Analysis of Antibody Drug Conjugate
9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Antibody Drug Conjugate in This Report
1.2 Commercial Types of Antibody Drug Conjugate
1.2.1 Adcetris
1.2.2 Kadcyl
1.2.3 Other
1.3 Downstream Application of Antibody Drug Conjugate
1.3.1 Hospital
1.3.2 Pharmaceutical Company
1.3.3 Research Institutions
1.4 Development History of Antibody Drug Conjugate
1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
1.5.1 Global Antibody Drug Conjugate Market Status and Trend 2013-2023
1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Antibody Drug Conjugate 2013-2017
2.2 Production Market of Antibody Drug Conjugate by Regions
2.2.1 Production Volume of Antibody Drug Conjugate by Regions
2.2.2 Production Value of Antibody Drug Conjugate by Regions
2.3 Demand Market of Antibody Drug Conjugate by Regions
2.4 Production and Demand Status of Antibody Drug Conjugate by Regions
2.4.1 Production and Demand Status of Antibody Drug Conjugate by Regions 2013-2017
2.4.2 Import and Export Status of Antibody Drug Conjugate by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Antibody Drug Conjugate by Types
3.2 Production Value of Antibody Drug Conjugate by Types
3.3 Market Forecast of Antibody Drug Conjugate by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry
4.2 Market Forecast of Antibody Drug Conjugate by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE
5.1 Global Economy Situation and Trend Overview
5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Antibody Drug Conjugate by Major Manufacturers
6.2 Production Value of Antibody Drug Conjugate by Major Manufacturers
6.3 Basic Information of Antibody Drug Conjugate by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Manufacturer
6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Seattle Genetics/Takeda
7.1.1 Company profile
7.1.2 Representative Antibody Drug Conjugate Product
7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle Genetics/Takeda
7.2 Roche
7.2.1 Company profile
7.2.2 Representative Antibody Drug Conjugate Product
7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche
7.3 ImmunoGen
7.3.1 Company profile
7.3.2 Representative Antibody Drug Conjugate Product
7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen
7.4 Immunomedics
7.4.1 Company profile
7.4.2 Representative Antibody Drug Conjugate Product
7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics
7.5 Pfizer
7.5.1 Company profile
7.5.2 Representative Antibody Drug Conjugate Product
7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer
7.6 Celldex Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody Drug Conjugate Product
7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.7 Millennium Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Antibody Drug Conjugate Product
7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals
7.8 Bayer HealthCare
7.8.1 Company profile
7.8.2 Representative Antibody Drug Conjugate Product
7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer HealthCare
7.9 Mersana Therapeutics
7.9.1 Company profile
7.9.2 Representative Antibody Drug Conjugate Product
7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana Therapeutics
7.10 Heidelberg Pharma
7.10.1 Company profile
7.10.2 Representative Antibody Drug Conjugate Product
7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Heidelberg Pharma
7.11 Oxford BioTherapeutics
7.11.1 Company profile
7.11.2 Representative Antibody Drug Conjugate Product
7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Antibody Drug Conjugate Product
7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE
8.1 Industry Chain of Antibody Drug Conjugate
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE
9.1 Cost Structure Analysis of Antibody Drug Conjugate
9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate
9.3 Labor Cost Analysis of Antibody Drug Conjugate
9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
